Dr. Julia K. Rotow, MD

Dr. Rotow practices at Brigham and Women's Hospital in Boston, Massachusetts, part of Mass General Brigham.

Dr. Rotow's NPI, 1285996082, was assigned on June 8, 2012. Dr. Rotow graduated from University of California, Geffen School of Medicine in 2012. Dr. Rotow holds Massachusetts license 278941.

Dr. Rotow's primary practice is Brigham and Women's Hospital, at 75 Francis Street, Boston, MA 02115 in Suffolk County. The practice phone is (617) 732-5500.

Dr. Rotow's primary practice is Brigham and Women's Hospital in Boston, Massachusetts, part of Mass General Brigham. Dr. Rotow is also affiliated with Dana-Farber Cancer Institute. The medical group on file is Binney Medical Group. Dmand AI also links Dr. Rotow to 1 more hospital and 1 hospital outpatient department, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Rotow practices, 4 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. Rotow's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Rotow is licensed in Massachusetts.

CMS data shows 328 Medicare services from Dr. Rotow across 4 procedure codes in 2024, all of them office visits, for 144 Medicare patients. Medicare paid $29,378 for them.

CMS counts 144 Medicare patients who saw Dr. Rotow in 2024. The largest group is 65 to 74, with 82 patients. 75% of them have cancer, and 63% have high cholesterol. 15% are also on Medicaid. Their average risk score is 2.13, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Rotow's median patient age at 69, with 63% women.

In 2024, Dr. Rotow wrote 240 Medicare Part D claims for 70 patients. 62% of them were for generic drugs. CMS names the drug for 126 of them, across 6 drugs with 11 or more claims each, at $650,901 in total drug cost. In 2023, CMS named 157 claims across 5 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 84 out of 100 for Dr. Rotow for performance year 2024, reported as part of a group. Dr. Rotow accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Rotow as offering telehealth.

Dmand AI links 30 papers to Dr. Rotow, published from 2013 to 2025. 2023 was the busiest year, with 5. The most frequent topics are Lung Neoplasms, Carcinoma, Non-Small-Cell Lung and ErbB Receptors. Dr. Rotow has published most often in J Clin Oncol. Dr. Rotow's most frequent co-authors are Collin M. Blakely, MD, Caroline McCoach, MD and Trever Bivona, MD, PhD.

CMS Open Payments shows 203 general payments to Dr. Rotow from 23 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 87% of the total. AstraZeneca Pharmaceuticals LP paid the most, $114,630. It also lists 3 research payments totaling $169 from 2024 to 2025, naming 1 clinical trial.

Dr. Rotow graduated from University of California, Geffen School of Medicine in 2012.